Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss. Improving distant control of lung cancer is the most exciting potential benefit of combining ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

New Zealand’s most famous office comedy, a raucous play about rowdy high schoolers, a West Auckland tribute, a lesson on how ...

Following on from previous singles, the haunting ‘This River’, and evocative ‘S.O.B.’, Hayes once again delivers a rich blend ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma.

Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...